Mimedx (MDXG) Net Income towards Common Stockholders Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.97% |
| Dec 31, 2024 | 24.53% |
| Sep 30, 2024 | -8.64% |
| Jun 30, 2024 | 24.77% |
| Mar 31, 2024 | 21.82% |
| Dec 31, 2023 | 26.49% |
| Sep 30, 2023 | 110.89% |
| Jun 30, 2023 | 33.05% |
| Mar 31, 2023 | -22.73% |
| Dec 31, 2022 | -2.80% |
| Sep 30, 2022 | -22.37% |
| Jun 30, 2022 | -32.30% |
| Mar 31, 2022 | -32.58% |
| Dec 31, 2021 | 25.53% |
| Sep 30, 2021 | -26.02% |
| Jun 30, 2021 | -29.62% |
| Mar 31, 2021 | -59.21% |
| Dec 31, 2020 | -27.35% |
| Sep 30, 2020 | -58.28% |
| Jun 30, 2020 | -28.90% |
| Mar 31, 2020 | -26.03% |
| Dec 31, 2019 | -31.62% |
| Sep 30, 2019 | 27.32% |
| Jun 30, 2019 | -113.28% |
| Mar 31, 2019 | -70.47% |
| Dec 31, 2018 | -90.95% |
| Sep 30, 2018 | 10.34% |
| Jun 30, 2018 | 34.38% |
| Mar 31, 2018 | 37.14% |
| Dec 31, 2017 | 50.95% |
| Sep 30, 2017 | 39.15% |
| Jun 30, 2017 | 59.05% |
| Mar 31, 2017 | 48.69% |
| Dec 31, 2016 | -18.82% |
| Sep 30, 2016 | 31.15% |
| Jun 30, 2016 | 22.77% |
| Mar 31, 2016 | 18.71% |